BioAlliance Pharma Announces the Grant of Its Main Patent on The Lauriad Technology in Europe
The patent has been validated in the main European countries and the opposition period has now expired
"The grant of this patent acknowledges the true innovation behind the Lauriad® muco-adhesive technology", stated Dominique Costantini, President and CEO of BioAlliance Pharma. "It reinforces our positioning in the target markets for the Lauriad® technology: oropharyngeal candidiasis, labial herpes and chronic pain".
BioAlliance Pharma's patent portfolio now encompasses 25 published patent families (comprising 196 patent applications and granted patents) covering innovative technologies or products in the fields of opportunistic infections, cancer and AIDS. More than half the portfolio is made up of granted patents.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.